CTLA4 and neoplasm: Since the first U.S. Food and Drug Administration (FDA) approval of ipilimumab, a CTLA-4 monoclonal antibody, in 2011 for the treatment of metastatic melanoma[6], ICIs have transformed the treatment landscape across multiple tumour types[7].